Ya-Wei Xu
Overview
Explore the profile of Ya-Wei Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chi C, Teliewubai J, Lu Y, Fan X, Yu S, Xiong J, et al.
Lipids Health Dis
. 2018 Aug;
17(1):199.
PMID: 30144803
Background: Recommendations of non-HDL amplification varied from different guidelines. We aim to test the relationships between various lipid parameters and target organ damage (TOD) including aortic stiffness, peripheral arterial disease...
12.
Zhou Y, Zhao Y, Zhao X, Liang C, Xu Y, Li L, et al.
Curr Med Sci
. 2018 Aug;
38(2):222-228.
PMID: 30074179
Finding the novel drug from the effective components of traditional Chinese herbal medicine is a hotspot of the modern pharmacological research. Hyperoside (HYP) belongs to flavonoid glycosides, and it has...
13.
Jiang J, Wang L, Huang D, Huang S, Zhu Z, Xu Y, et al.
Huan Jing Ke Xue
. 2018 Jul;
37(12):4712-4719.
PMID: 29965312
To further unravel adsorption mechanisms of effluent organic matter (EfOM) on the PVDF ultrafiltration membranes modified by nano-silica particles from micro perspective during different filtration phases, the membranes were prepared...
14.
Xiong J, Liu X, Gong Y, Zhang P, Qiang S, Zhao Q, et al.
J Mol Cell Cardiol
. 2018 Feb;
117:26-35.
PMID: 29477366
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition that is characterized by an abnormal heart rhythm in response to physical or emotional stress. The majority CPVT patients carry mutations in...
15.
Wang H, Liu H, Cao H, Qiao Z, Xu Y
Med Sci Monit
. 2018 Jan;
24:246-253.
PMID: 29329279
BACKGROUND Diosgenin, a phytosteroid sapogenin, has anti-inflammatory properties shown to reduce myocardial ischemia-reperfusion injury (MIRI). However, the specific mechanism by which this is achieved is not clear. This study investigated...
16.
Tang K, Zhao Y, Li H, Zhu M, Li W, Liu W, et al.
J Am Heart Assoc
. 2017 Apr;
6(4).
PMID: 28432072
Background: Translocase of inner membrane 50 (TIM50) is a member of the translocase of inner membrane (TIM) complex in the mitochondria. Previous research has demonstrated the role of TIM50 in...
17.
Chen S, Santoso T, Zhang J, Ye F, Xu Y, Fu Q, et al.
Circ Cardiovasc Interv
. 2017 Jan;
10(2).
PMID: 28122805
Background: Provisional stenting is effective for anatomic simple bifurcation lesions. Double kissing crush stenting reduces the 1-year rate of target lesion revascularization. This study aimed to investigate the 5-year clinical...
18.
Lu Y, Xu D, Zhao Y, Zhu G, Zhu M, Liu W, et al.
J Am Heart Assoc
. 2016 Dec;
5(11).
PMID: 27912208
Background: Smad nuclear interacting protein 1 (SNIP1) plays a critical role in cell proliferation, transformation of embryonic fibroblasts, and immune regulation. However, the role of SNIP1 in cardiac hypertrophy remains...
19.
Li W, Zhao Y, Zhu G, Peng W, Zhu M, Yu X, et al.
Clin Sci (Lond)
. 2016 Oct;
131(2):141-154.
PMID: 27702885
Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual specific phosphatase...
20.
Yang Y, Huo Y, Xu Y, Wang J, Han Y, Ge J, et al.
Chin Med J (Engl)
. 2016 Aug;
129(17):2058-62.
PMID: 27569231
Background: The primary cause of ischemic heart failure (HF) is myocardial infarction (MI) resulting in left ventricle (LV) wall motion abnormality secondary to ventricular remodeling. A prospective, nonrandomized study conducted...